Merck (MRK) Stock Moves 0.27%: What You Should Know

11.06.24 23:50 Uhr

Werte in diesem Artikel
Aktien

115,40 EUR 0,20 EUR 0,17%

151,95 EUR -1,10 EUR -0,72%

Indizes

PKT PKT

PKT PKT

1.592,0 PKT -14,5 PKT -0,90%

18.387,5 PKT -170,2 PKT -0,92%

7.064,0 PKT -65,4 PKT -0,92%

2.975,3 PKT 0,8 PKT 0,03%

2.143,9 PKT 0,6 PKT 0,03%

185,3 PKT -2,3 PKT -1,23%

39.853,9 PKT -504,2 PKT -1,25%

502,3 PKT -5,0 PKT -0,99%

9.713,6 PKT -88,5 PKT -0,90%

18.361,0 PKT -186,0 PKT -1,00%

18.358,5 PKT -206,6 PKT -1,11%

15.697,3 PKT -10,1 PKT -0,06%

7.191,2 PKT -66,1 PKT -0,91%

15.834,6 PKT -138,2 PKT -0,87%

2.616,7 PKT -71,8 PKT -2,67%

5.427,1 PKT -128,6 PKT -2,31%

18.338,1 PKT -206,6 PKT -1,11%

In the latest trading session, Merck (MRK) closed at $131.84, marking a +0.27% move from the previous day. The stock traded in line with S&P 500. On the other hand, the Dow registered a loss of 0.31%, and the technology-centric Nasdaq increased by 0.88%.Shares of the pharmaceutical company witnessed a gain of 1.7% over the previous month, trailing the performance of the Medical sector with its gain of 2.89% and the S&P 500's gain of 2.85%.The upcoming earnings release of Merck will be of great interest to investors. The company's earnings report is expected on July 30, 2024. The company's upcoming EPS is projected at $2.14, signifying a 203.88% increase compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $15.88 billion, up 5.65% from the prior-year quarter.For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $8.62 per share and a revenue of $64.4 billion, representing changes of +470.86% and +7.13%, respectively, from the prior year.Any recent changes to analyst estimates for Merck should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.67% lower. At present, Merck boasts a Zacks Rank of #3 (Hold).Looking at valuation, Merck is presently trading at a Forward P/E ratio of 15.25. Its industry sports an average Forward P/E of 14.5, so one might conclude that Merck is trading at a premium comparatively.It's also important to note that MRK currently trades at a PEG ratio of 2.54. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 1.77 based on yesterday's closing prices.The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 152, putting it in the bottom 40% of all 250+ industries.The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.Where Will Stocks Go…If Biden Wins? If Trump Wins?The answers may surprise you.Since 1950, even after negative midterm years, the market has never had a lower presidential election year. With voters energized and engaged, the market has been almost unrelentingly bullish no matter which party wins!Now is the time to download Zacks' free Special Report with 5 stocks that offer extreme upside for both Democrats and Republicans…1. Medical manufacturer has gained +11,000% in the last 15 years.2. Rental company is absolutely crushing its sector.3. Energy powerhouse plans to grow its already large dividend by 25%.4. Aerospace and defense standout just landed a potentially $80 billion contract.5. Giant Chipmaker is building huge plants in the U.S. Hurry, Download Special Report FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Merck

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Merck

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Merck KGaA

Analysen zu Merck KGaA

DatumRatingAnalyst
23.07.2024Merck OverweightBarclays Capital
23.07.2024Merck OverweightBarclays Capital
18.07.2024Merck BuyJefferies & Company Inc.
18.07.2024Merck OverweightJP Morgan Chase & Co.
18.07.2024Merck BuyJefferies & Company Inc.
DatumRatingAnalyst
23.07.2024Merck OverweightBarclays Capital
23.07.2024Merck OverweightBarclays Capital
18.07.2024Merck BuyJefferies & Company Inc.
18.07.2024Merck OverweightJP Morgan Chase & Co.
18.07.2024Merck BuyJefferies & Company Inc.
DatumRatingAnalyst
25.06.2024Merck Market-PerformBernstein Research
06.12.2023Merck HaltenDZ BANK
27.11.2023Merck HaltenDZ BANK
27.04.2023Merck HaltenDZ BANK
10.11.2022Merck NeutralUBS AG
DatumRatingAnalyst
06.03.2023Merck VerkaufenDZ BANK
02.03.2023Merck SellGoldman Sachs Group Inc.
07.02.2023Merck SellGoldman Sachs Group Inc.
02.02.2023Merck VerkaufenDZ BANK
15.11.2022Merck SellGoldman Sachs Group Inc.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Merck KGaA nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"